{"id":"clevudine","rwe":[{"pmid":"38584189","year":"2024","title":"DFT/TDDFT calculations of geometry optimization, electronic structure and spectral properties of clevudine and telbivudine for treatment of chronic hepatitis B.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"36423233","year":"2022","title":"Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens.","finding":"","journal":"Antiviral chemistry & chemotherapy","studyType":"Clinical Study"},{"pmid":"36331415","year":"2022","title":"Protecting-group-free synthesis of clevudine (L-FMAU), a treatment of the hepatitis B virus.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"},{"pmid":"36201354","year":"2023","title":"A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection.","finding":"","journal":"Journal of viral hepatitis","studyType":"Clinical Study"},{"pmid":"34700113","year":"2021","title":"Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization.","finding":"","journal":"International immunopharmacology","studyType":"Clinical Study"}],"tags":[{"label":"clevudine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J05AF12","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic type B viral hepatitis","category":"indication"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"levovir","offLabel":[],"synonyms":["clevudine","levovir"],"timeline":[],"approvals":[],"brandName":"Levovir","ecosystem":[{"indication":"Chronic type B viral hepatitis","otherDrugs":[{"name":"adefovir dipivoxil","slug":"adefovir-dipivoxil","company":"Gilead"},{"name":"entecavir","slug":"entecavir","company":"Bristol Myers Squibb"},{"name":"interferon alfa-2b","slug":"interferon-alfa-2b","company":"Schering"},{"name":"lamivudine","slug":"lamivudine","company":"Viiv Hlthcare"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"clevudine","explanation":"Imagine your body's cells are like factories that make proteins. The hepatitis B virus takes over these factories and makes more viruses. Levovir stops the virus from making copies of itself by blocking the enzymes it needs to replicate.","oneSentence":"Levovir works by inhibiting viral DNA synthesis, specifically targeting the hepatitis B virus.","technicalDetail":"Levovir, a clevudine, acts as a nucleoside analog that inhibits viral DNA polymerase, preventing the hepatitis B virus from replicating by terminating viral DNA chain elongation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Clevudine","title":"Clevudine","extract":"Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4394","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLEVUDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLEVUDINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Clevudine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:06:39.909821","biosimilars":[],"competitors":[{"drugName":"zidovudine","drugSlug":"zidovudine","fdaApproval":"1987-03-19","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"didanosine","drugSlug":"didanosine","fdaApproval":"1991-10-09","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"zalcitabine","drugSlug":"zalcitabine","fdaApproval":"1992-06-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"stavudine","drugSlug":"stavudine","fdaApproval":"1994-06-24","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lamivudine","drugSlug":"lamivudine","fdaApproval":"1995-11-17","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"abacavir","drugSlug":"abacavir","fdaApproval":"1998-12-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tenofovir disoproxil","drugSlug":"tenofovir-disoproxil","fdaApproval":"2001-10-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"adefovir dipivoxil","drugSlug":"adefovir-dipivoxil","fdaApproval":"2002-09-20","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"emtricitabine","drugSlug":"emtricitabine","fdaApproval":"2003-07-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"entecavir","drugSlug":"entecavir","fdaApproval":"2005-03-29","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telbivudine","drugSlug":"telbivudine","fdaApproval":"2006-10-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tenofovir alafenamide","drugSlug":"tenofovir-alafenamide","fdaApproval":"2015-11-05","patentExpiry":"Feb 15, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"clevudine","indications":{"approved":[{"name":"Chronic type B viral hepatitis","source":"DrugCentral","snomedId":61977001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"zidovudine","brandName":"zidovudine","genericName":"zidovudine","approvalYear":"1987","relationship":"same-class"},{"drugId":"didanosine","brandName":"didanosine","genericName":"didanosine","approvalYear":"1991","relationship":"same-class"},{"drugId":"zalcitabine","brandName":"zalcitabine","genericName":"zalcitabine","approvalYear":"1992","relationship":"same-class"},{"drugId":"stavudine","brandName":"stavudine","genericName":"stavudine","approvalYear":"1994","relationship":"same-class"},{"drugId":"lamivudine","brandName":"lamivudine","genericName":"lamivudine","approvalYear":"1995","relationship":"same-class"},{"drugId":"abacavir","brandName":"abacavir","genericName":"abacavir","approvalYear":"1998","relationship":"same-class"},{"drugId":"tenofovir-disoproxil","brandName":"tenofovir disoproxil","genericName":"tenofovir disoproxil","approvalYear":"2001","relationship":"same-class"},{"drugId":"adefovir-dipivoxil","brandName":"adefovir dipivoxil","genericName":"adefovir dipivoxil","approvalYear":"2002","relationship":"same-class"},{"drugId":"emtricitabine","brandName":"emtricitabine","genericName":"emtricitabine","approvalYear":"2003","relationship":"same-class"},{"drugId":"entecavir","brandName":"entecavir","genericName":"entecavir","approvalYear":"2005","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04752267","phase":"EARLY_PHASE1","title":"18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2021-02-15","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Glioma","Malignant Brain Neoplasm","Metastatic Breast Carcinoma","Metastatic Colon Carcinoma","Metastatic Kidney Carcinoma","Metastatic Lung Carcinoma","Metastatic Malignant Neoplasm in the Brain","Metastatic Melanoma","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8"],"enrollment":10,"completionDate":"2023-09-18"},{"nctId":"NCT02079181","phase":"NA","title":"18F-FMAU PET/CT in Imaging Patients With Advanced Cancers","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2014-01-31","conditions":["Malignant Neoplasm"],"enrollment":3,"completionDate":"2023-08-22"},{"nctId":"NCT02809690","phase":"PHASE1","title":"18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2016-09-12","conditions":["Prostate Neoplasm"],"enrollment":18,"completionDate":"2021-07-21"},{"nctId":"NCT01712815","phase":"NA","title":"PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2013-11-22","conditions":["HER2-positive Breast Cancer","Recurrent Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer"],"enrollment":12,"completionDate":"2022-11-01"},{"nctId":"NCT00823342","phase":"PHASE3","title":"ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-12-14","conditions":["HBe Negative Chronic Hepatitis B","Hepatitis B Viral Infection"],"enrollment":150,"completionDate":"2008-12-14"},{"nctId":"NCT05298332","phase":"PHASE1","title":"Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects","status":"TERMINATED","sponsor":"Antios Therapeutics, Inc","startDate":"2022-03-29","conditions":["Chronic Hepatitis b"],"enrollment":37,"completionDate":"2022-08-22"},{"nctId":"NCT04847440","phase":"PHASE2","title":"A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection","status":"TERMINATED","sponsor":"Antios Therapeutics, Inc","startDate":"2021-03-30","conditions":["Hepatitis B, Chronic","Hepatitis D"],"enrollment":40,"completionDate":"2022-09-01"},{"nctId":"NCT04891302","phase":"PHASE2","title":"The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2021-03-19","conditions":["COVID-19"],"enrollment":104,"completionDate":"2021-07-08"},{"nctId":"NCT04347915","phase":"PHASE2","title":"The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2020-05-26","conditions":["COVID-19"],"enrollment":64,"completionDate":"2021-02-26"},{"nctId":"NCT05238844","phase":"PHASE2","title":"A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Antios Therapeutics, Inc","startDate":"2022-04-11","conditions":["Chronic Hepatitis b"],"enrollment":2,"completionDate":"2022-05-25"},{"nctId":"NCT05137548","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects","status":"COMPLETED","sponsor":"Antios Therapeutics, Inc","startDate":"2021-10-27","conditions":["Drug Interaction"],"enrollment":32,"completionDate":"2021-12-23"},{"nctId":"NCT05137600","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects","status":"COMPLETED","sponsor":"Antios Therapeutics, Inc","startDate":"2021-10-28","conditions":["Drug Drug Interaction"],"enrollment":36,"completionDate":"2022-01-23"},{"nctId":"NCT04248426","phase":"PHASE1","title":"A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Antios Therapeutics, Inc","startDate":"2020-02-05","conditions":["Hepatitis B, Chronic"],"enrollment":88,"completionDate":"2021-05-18"},{"nctId":"NCT01812668","phase":"NA","title":"Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2013-03","conditions":["Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer"],"enrollment":20,"completionDate":"2019-06-18"},{"nctId":"NCT00362505","phase":"PHASE3","title":"Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2004-06","conditions":["Hepatitis B"],"enrollment":0,"completionDate":"2006-03"},{"nctId":"NCT00313287","phase":"PHASE3","title":"Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2003-06","conditions":["Hepatitis B"],"enrollment":180,"completionDate":"2004-11"},{"nctId":"NCT00362700","phase":"PHASE2","title":"Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2003-07","conditions":["Hepatitis B"],"enrollment":33,"completionDate":"2005-10"},{"nctId":"NCT00313274","phase":"PHASE3","title":"Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2003-07","conditions":["Hepatitis B"],"enrollment":80,"completionDate":"2004-12"},{"nctId":"NCT01264094","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2009-11","conditions":["Chronic Hepatitis B"],"enrollment":200,"completionDate":"2015-06"},{"nctId":"NCT01263002","phase":"PHASE4","title":"A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2010-06","conditions":["Hepatitis B Associated Hepatocellular Carcinoma"],"enrollment":33,"completionDate":"2013-09"},{"nctId":"NCT01264367","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2008-12","conditions":["HBeAg(+) Chronic Hepatitis B"],"enrollment":60,"completionDate":"2014-05"},{"nctId":"NCT00672867","phase":"PHASE3","title":"A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2007-12","conditions":["Patients With LC-B"],"enrollment":102,"completionDate":"2014-09"},{"nctId":"NCT01264354","phase":"PHASE4","title":"An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2010-03","conditions":["Chronic Hepatitis B"],"enrollment":60,"completionDate":"2013-02"},{"nctId":"NCT01266005","phase":"PHASE4","title":"A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2009-08","conditions":["Chronic Hepatitis B"],"enrollment":75,"completionDate":"2014-01"},{"nctId":"NCT01264133","phase":"PHASE4","title":"A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2009-09","conditions":["Chronic Hepatitis B"],"enrollment":200,"completionDate":"2014-12"},{"nctId":"NCT01192854","phase":"PHASE3","title":"An Study of Efficacy and Safety of Clevudine","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-02","conditions":["Chronic Hepatitis B"],"enrollment":288,"completionDate":"2011-05"},{"nctId":"NCT00313261","phase":"PHASE2","title":"Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2003-06","conditions":["Hepatitis B"],"enrollment":0,"completionDate":"2005-02"},{"nctId":"NCT01581242","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2012-04","conditions":["Healthy"],"enrollment":42,"completionDate":""},{"nctId":"NCT00558493","phase":"PHASE4","title":"Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2007-11","conditions":["Chronic Hepatitis B"],"enrollment":100,"completionDate":""},{"nctId":"NCT00362635","phase":"PHASE3","title":"Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2006-08","conditions":["Hepatitis B"],"enrollment":92,"completionDate":""},{"nctId":"NCT01264107","phase":"","title":"An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2009-04","conditions":["Chronic Hepatitis B"],"enrollment":37,"completionDate":"2012-04"},{"nctId":"NCT00558818","phase":"PHASE4","title":"Long-term Study With Clevudine","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2007-06","conditions":["Chronic Hepatitis B"],"enrollment":150,"completionDate":"2011-09"},{"nctId":"NCT01595633","phase":"PHASE4","title":"Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-03","conditions":["Chronic Hepatitis B"],"enrollment":124,"completionDate":"2014-02"},{"nctId":"NCT00641082","phase":"PHASE4","title":"A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2008-02","conditions":["HBeAg(-) Chronic Hepatitis B With Compensated Liver Function"],"enrollment":43,"completionDate":""},{"nctId":"NCT00798460","phase":"PHASE4","title":"Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Inje University","startDate":"2008-12","conditions":["Chronic Hepatitis B"],"enrollment":30,"completionDate":"2010-11"},{"nctId":"NCT00501124","phase":"PHASE4","title":"Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2007-05","conditions":["Hepatitis B"],"enrollment":70,"completionDate":""},{"nctId":"NCT00496002","phase":"PHASE3","title":"Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus","status":"TERMINATED","sponsor":"Pharmasset","startDate":"2007-08","conditions":["Chronic Hepatitis","Hepatitis B"],"enrollment":0,"completionDate":""},{"nctId":"NCT00496158","phase":"PHASE3","title":"Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus","status":"TERMINATED","sponsor":"Pharmasset","startDate":"2007-08","conditions":["Chronic Hepatitis","Hepatitis B"],"enrollment":0,"completionDate":""},{"nctId":"NCT00305019","phase":"PHASE2","title":"Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus","status":"TERMINATED","sponsor":"Bukwang Pharmaceutical","startDate":"2002-07","conditions":["Hepatitis B"],"enrollment":120,"completionDate":"2004-03"},{"nctId":"NCT00044135","phase":"PHASE2","title":"A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.","status":"UNKNOWN","sponsor":"Triangle Pharmaceuticals","startDate":"2002-08","conditions":["Hepatitis B"],"enrollment":30,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"IN51MVP5F1","CHEBI":"CHEBI:135964","INN_ID":"7684","UMLSCUI":"C0045212","ChEMBL_ID":"CHEMBL458875","KEGG_DRUG":"D03537","DRUGBANK_ID":"DB06683","PUBCHEM_CID":"73115","MESH_SUPPLEMENTAL_RECORD_UI":"C034935"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":133,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AF12","allCodes":["J05AF12"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Apr 8","pmid":"38584189","title":"DFT/TDDFT calculations of geometry optimization, electronic structure and spectral properties of clevudine and telbivudine for treatment of chronic hepatitis B.","journal":"Scientific reports"},{"date":"2022 Jan-Dec","pmid":"36423233","title":"Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens.","journal":"Antiviral chemistry & chemotherapy"},{"date":"2022 Nov 23","pmid":"36331415","title":"Protecting-group-free synthesis of clevudine (L-FMAU), a treatment of the hepatitis B virus.","journal":"Organic & biomolecular chemistry"},{"date":"2023 Jan","pmid":"36201354","title":"A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection.","journal":"Journal of viral hepatitis"},{"date":"2021 Dec","pmid":"34700113","title":"Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization.","journal":"International immunopharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levovir, also known as Clevudine, is a small molecule clevudine drug developed by an unknown original developer. It is currently owned by an unknown entity. Levovir is approved to treat Chronic type B viral hepatitis. The commercial status of Levovir is unknown, and it may be patented or generic. Key safety considerations are not specified.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}